p107 Antibody (SD9): sc-250

p107 Antibody (SD9) is a mouse monoclonal IgG1 kappa light chain antibody designed to detect the full-length human p130 protein, also known as RBL2 or Retinoblastoma-like protein 2, across mouse, rat, and human species using western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF) techniques. p130 protein is a crucial member of the retinoblastoma (Rb) family of tumor suppressors, characterized by conserved pocket domains that facilitate interactions with E2F transcription factors. p130 is located predominantly in the nucleus and plays an essential role in regulating the cell cycle by controlling the transition from G1 to S phase, thereby maintaining cellular quiescence and preventing uncontrolled cell proliferation that can lead to tumorigenesis. p130 forms complexes with other regulatory proteins, enabling modulation of gene expression and chromatin remodeling, which are vital for cellular differentiation and maintaining genomic stability. p107 mouse monoclonal antibody (SD9) allows researchers to investigate p130 expression patterns, protein interactions, and functional mechanisms within various cellular contexts. p107 monoclonal antibody (SD9) supports research in understanding p130′s role in cell cycle regulation and interactions with key signaling pathways, critical for elucidating the molecular basis of cancer and developing targeted therapeutic strategies. p107 monoclonal antibody (SD9) enables advanced studies in tumor suppression, cellular proliferation, and the intricate network of pathways that maintain cellular homeostasis, making p107 monoclonal antibody (SD9) an indispensable tool for researchers aiming to uncover the complexities of cell cycle control and implications in cancer biology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p107 Antibody (SD9) References:

1. Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner.  |  Lees, E., et al. 1992. Genes Dev. 6: 1874-85. PMID: 1398067
2. Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.  |  Barbie, TU., et al. 2003. Proc Natl Acad Sci U S A. 100: 15601-6. PMID: 14671316
3. p107 inhibits G1 to S phase progression by down-regulating expression of the F-box protein Skp2.  |  Rodier, G., et al. 2005. J Cell Biol. 168: 55-66. PMID: 15631990
4. A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F.  |  Helin, K., et al. 1992. Cell. 70: 337-50. PMID: 1638634
5. The E2F transcription factor is a cellular target for the RB protein.  |  Chellappan, SP., et al. 1991. Cell. 65: 1053-61. PMID: 1828392
6. The T/E1A-binding domain of the retinoblastoma product can interact selectively with a sequence-specific DNA-binding protein.  |  Chittenden, T., et al. 1991. Cell. 65: 1073-82. PMID: 1828394
7. Cyclin A and the retinoblastoma gene product complex with a common transcription factor.  |  Bandara, LR., et al. 1991. Nature. 352: 249-51. PMID: 1830372
8. Distinct roles for p107 and p130 in Rb-independent cellular senescence.  |  Lehmann, BD., et al. 2008. Cell Cycle. 7: 1262-8. PMID: 18418057
9. Identification of a cellular transcription factor involved in E1A trans-activation.  |  Kovesdi, I., et al. 1986. Cell. 45: 219-28. PMID: 2938741
10. p107 Deficiency Increases Energy Expenditure by Inducing Brown-Fat Thermogenesis and Browning of White Adipose Tissue.  |  Cunarro, J., et al. 2019. Mol Nutr Food Res. 63: e1801096. PMID: 30383332
11. RBL1/p107 Expression Levels Are Modulated by Multiple Signaling Pathways.  |  Ventura, E., et al. 2021. Cancers (Basel). 13: PMID: 34638509
12. p107 mediated mitochondrial function controls muscle stem cell proliferative fates.  |  Bhattacharya, D., et al. 2021. Nat Commun. 12: 5977. PMID: 34645816

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-p107 Antibody (SD9) has 81 citations in a variety of scientific publications.

Primary antibodies like Anti-p107 Antibody (SD9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

p107 Antibody (SD9) Specifications

Alternate Product Name: RBL1

Product Clone Name: SD9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: p107

Epitope Species: human

Product Reactivity/Detection: p107

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 81 citations in various scientific publications

Available Conjugates/Forms for p107 Antibody (SD9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin, X: TransCruz Reagent